Skip to main content
Kenneth Ataga, MD, Oncology, Memphis, TN, Regional One Health

KennethIAtagaMD

Oncology • Memphis, TN

Hematologic Oncology

Associate Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Ataga is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ataga's full profile

Already have an account?

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1997 - 2000
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityResidency, Internal Medicine, 1994 - 1997
  • University of Benin Faculty of Medicine
    University of Benin Faculty of MedicineClass of 1990

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2018 - 2026
  • NC State Medical License
    NC State Medical License 1997 - 2025
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2011

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Renin‐Angiotensin‐Aldosterone System Blocking Agents on Progression of Glomerulopathy in Sickle Cell Disease  
    Vimal K Derebail, Kenneth I Ataga, British Journal of Haematology

Abstracts/Posters

  • Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study
    Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Opioid Analgesics Are Associated with Albuminuria in Adult Patients with Sickle Cell Anemia
    Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Progression of Central Nervous System Vasculopathy in Young Adults with Sickle Cell Anemia
    Kenneth I. Ataga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomize... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Advancing Science in Sickle Cell Disease: Implications for the Future of Care 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • TN Doctor Leading $3 Million AI Study for Predicting Kidney Function Decline in Sickle Cell Patients
    TN Doctor Leading $3 Million AI Study for Predicting Kidney Function Decline in Sickle Cell PatientsOctober 30th, 2021
  • Promising New Sickle Cell Disease Medicine Wins FDA Approval
    Promising New Sickle Cell Disease Medicine Wins FDA ApprovalNovember 18th, 2019
  • FDA Approves Novartis Drug to Treat Pain Crises in Sickle Cell Disease
    FDA Approves Novartis Drug to Treat Pain Crises in Sickle Cell DiseaseNovember 16th, 2019
  • Join now to see all

Grant Support

  • Endothelial Dysfunction In The Pathogenesis Of Sickle Cell NephropathyNational Heart, Lung, And Blood Institute2012
  • Coagulation Activation In Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2010
  • Eptifibatide As Treatment For Acute Pain Episodes In Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2008–2009
  • Pulmonary Hypertension In Sickle Cell Disease With Identification Of Clinical AsNational Center For Research Resources2008
  • Clinical Trial: Phase III, Ica-17043 With Or Without Hydroxyurea In Sickle CellNational Center For Research Resources2008
  • Clinical Trial: Longterm Safety Of Ica-17043 With Or Without Hydroxyurea In SickNational Center For Research Resources2008
  • Clinical Trial: Impacts Trial: Investigation Of The Modulation Of PhospholipaseNational Center For Research Resources2008
  • Clinical Trial: Bosentan In Sickle Cell Patients With Symptomatic Pulmonary HypeNational Center For Research Resources2008
  • Clinical Trial: Bosentan In Patients With Symptomatic Pulmonary Hypertension &SNational Center For Research Resources2008
  • Clinical Trial: Arginine Supplementation In Sickle Cell Anemia: Physiological ANational Center For Research Resources2008
  • 6R-BH4 In Subjects With Sickle Cell DiseaseNational Center For Research Resources2008
  • Effect Of Hydroxyurea On Blood Coagulation In Patient With Sickle Cell DiseaseNational Center For Research Resources2005–2008
  • Prevalence Of Pulmonary Hypertension In Sickle Cell DiseaseNational Center For Research Resources2004–2008
  • Longterm Safety Of Ica-17043 With Or Without Hydroxyurea In Sickle Cell PatientsNational Center For Research Resources2007
  • Bosentan In Sickle Cell Patients With Symptomatic Pulmonary HypertensionNational Center For Research Resources2007
  • Bosentan In Patients With Symptomatic Pulmonary Hypertension &Sickle CellNational Center For Research Resources2007
  • Phase III, Ica-17043 With Or Without Hydroxyurea In Sickle Cell DiseaseNational Center For Research Resources2006–2007
  • Arginine Supplementation In Sickle Cell Anemia: Physiological And ProphylacticNational Center For Research Resources2005–2007
  • The Effect Of Anticoagulation In Sickle Cell AnemiaNational Center For Research Resources2005–2006
  • Disordered Blood Coagulation In Sickle Cell DiseaseNational Center For Research Resources2002–2006

Hospital Affiliations

Dr. Kenneth Ataga, Dr. Kenneth Ataga, MD, Dr. K Ataga, Dr. Kenneth I Ataga